Non-Small Cell Lung Cancer Case Review

Multiple treatment modalities (including surgery, systemic therapy, and/or radiation therapy) may be options for patients with non-metastatic NSCLC, depending on disease stage, resectability, biomarker status, and other patient-specific factors. Additionally, recent clinical evidence has demonstrated that certain patients with non-metastatic NSCLC may be eligible for novel systemic therapy regimens. Clinicians need to be informed about key factors to consider when determining the most appropriate treatment approach for those with non-metastatic disease.

The number of actionable oncogenic drivers and types of targeted therapy agents for the treatment of metastatic NSCLC continue to increase. Due to the evolving treatment landscape, clinicians should understand the importance of using molecular testing to inform treatment strategy for patients with advanced or metastatic NSCLC.

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to: 

  • Describe the role of a multidisciplinary team in determining treatment approach for patients with non-metastatic non-small cell lung cancer.
  • Recognize how molecular testing can inform treatment strategy for patients with non-metastatic non-small cell lung cancer.
  • Recognize the importance of molecular testing in patients with metastatic non-small cell lung cancer.
  • Review the types of systemic therapy that may be used to treat patients with metastatic non-small cell lung cancer.

You may also be interested in

Recorded Presentations from the NCCN 2025 Lung Cancer Congress

This congress focuses on providing education for the interprofessional oncology care team with practical guidance on the latest updates to the NCCN Guidelines, novel and emerging therapies, recent clinical research, and strategies to align new developments with current standards of care. 
Archived NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer

Due to recent FDA approvals, several types of perioperative systemic therapies are now available for the treatment of resectable non-metastatic non-small cell lung cancer.
Additional information
Supporters: 

This educational activity is supported by educational grants from: AstraZeneca; Exact Sciences; Johnson & Johnson; Novartis; PharmaEssentia; Puma Biotechnology; Recordati Rare Disease Inc.; Revolution Medicines; Sirtex; Taiho Oncology, Inc.

This educational activity is supported by independent medical educational grants from: AbbVie; ADC Therapeutics; GSK

Supported by independent educational grants from: Blue Earth Diagnostics; Daiichi Sankyo; Merck & Co., Inc., Rahway, NJ, USA

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.

This project has been made possible in part by a grant from Varian, a Siemens Healthineers company. 

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
    • 1.50 ANCC Pharmacology Contact Hours
  • 1.50 Participation
Course opens: 
06/15/2026
Course expires: 
03/01/2027
Part of: 
Recorded Presentations from the NCCN 2026 Annual Conference
Presenters
 
Lyudmila Bazhenova, MD
UC San Diego Moores Cancer Center

David E. Gerber, MD
UT Southwestern Simmons Comprehensive Cancer Center

Daniel Morgensztern, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
 
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 
 
Lyudmila Bazhenova, MD
AbbVie, Inc.: Scientific Advisor
AnHeart Therapeutics: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Bayer HealthCare: Scientific Advisor
Boehringer Ingelheim GmbH: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Daiichi- Sankyo Co.: Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Genentech, Inc.: Scientific Advisor
Gilead Sciences, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor
Natera, Inc.: Scientific Advisor
NEUVOGEN, Inc.: Scientific Advisor
Novocure GmbH: Scientific Advisor
Nuvalent: Scientific Advisor
Pfizer Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Scientific Advisor
Revolution Medicines, Inc.: Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor 
Summit Therapeutics Inc.: Scientific Advisor
Taiho Pharmaceuticals Co., Ltd.: Scientific Advisor
TeleGene™: Scientific Advisor
 
David E. Gerber, MD
AbbVie, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Scientific Advisor
Bayer HealthCare: Scientific Advisor
BerGenBio: Grant/Research Support
Catalyst Pharmaceuticals: Consulting Fee
Daiichi- Sankyo Co.: Scientific Advisor
EMD Serono: Scientific Advisor
Gilead Sciences, Inc.: Equity Interest/Stock Options
GSK: Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support
Novocure GmbH: Grant/Research Support
Oncoinvent (formerly BerGenBio ASA): Grant/Research Support
OncoSeer Diagnostics, Inc.: Intellectual Property Rights; Ownership/Partnership/Principal
Summit Therapeutics Inc.: Scientific Advisor
Taiho Pharmaceuticals Co., Ltd.: Scientific Advisor
 
Daniel Morgensztern, MD
AbbVie, Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Bayer HealthCare: Consulting Fee
Boehringer Ingelheim GmbH: Consulting Fee
Eli Lilly and Company: Consulting Fee
Johnson & Johnson: Consulting Fee
Natera, Inc.: Consulting Fee
Tubulis GmbH: Consulting Fee
 
NCCN Staff Disclosures
 
The planners listed below have the following relevant relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
 
Crystal S. Denlinger, MD
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Sanofi: Grant/Research Support
 
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses
NCCN designates this educational activity for a maximum of 1.50 contact hours. This activity offers 1.5 pharmacotherapeutic contact hours for nurses. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.50 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-061-H01-P
 
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until March 1, 2027. PAs should only claim credit commensurate with the extent of their participation.
 

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Continuing Certification (CC)

This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn 1.50 Lifelong Learning (Part II) credits. Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Surgery Continuous Certification (CC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the NCCN 2026 Annual Conference has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity 
Medical Genetics and Genomics
Radiology
 
Permission to Upload Credits
For ABIM, ABPath, and ABS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.
 
By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
    • 1.50 ANCC Pharmacology Contact Hours
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing